期刊文献+

同型半胱氨酸及其代谢因素与肾病综合征的相关性 被引量:2

Study on the Relationship between HCA as well as metabolic factor and Nephrotic Syndrome
原文传递
导出
摘要 目的探讨同型半胱氨酸(Hcy)及其代谢因素与肾病综合征(NS)的关系。方法选取40例肾病综合征患者为实验组,40名年龄、性别相匹配的健康人为对照组,比较两组间Hcy、叶酸(FA)、维生素B6(VB6)、维生素B12(VB12)、血脂、凝血及肾功能的异同,并分析实验组Hcy水平与其代谢因素的关系。结果(1)两组Hcy、FA、VB6、VB12、部分凝血活酶时间(APTF)、纤维蛋白原(FIB)和低密度脂蛋白(LDL)等比较有显著性差异(P〈0.01),实验组血脂及凝血机制显著异常;(2)Hcy与APTT、FA、VB6、VB12水平呈负相关,与FIB水平呈正相关,其中VB6对Hcy影响最大。结论Hcy及其代谢因素与NS密切相关,Hcy与APTT、FA、VB6、VB12水平呈负相关,与FIB水平呈正相关,其中VB6对Hcy影响最大。 Objective To explore the relationship between homocysteine (HCY)as well as its correlation factor and Nephrotic Syndrome(NS). Methods This study included two groups of subjects,40 patients of NS and 40 healthy persons as control whose age and gender matched to the patient group. ( 1 ) Compared the serum concentration of Hcy, folic acid ( FA), Vitamine B6 ( VB6 ) , Vitamine B12 ( VB12 ), low density lipoprotein-cholesterol( LDL-C), fibrinogen(FIB) as well as activated partial thromboplastin time (APTT) in the two groups. T test was used for statistic analyse. (2)To analyze the relationship by linear regression between the serum concentration of Hcy and other factors in the patient group. Results ( 1 ) There were significant difference of Hcy, FA, VB6 , VB12, APTT, FIB, LDL between the patient group and the control group( P 〈0.001 ). The abnormality in the field of blood fat and clotting mechanism is more serious in experiment group than in the control group. (2) Analyzing all kinds of factors which take part in the metabolism of Hcy through logistic equation, we can arrive at the standard regression coefficient: APTT- 0. 120,VB6 -0.539,VB12 -0. 202,FA -0. 115 ,FIB 0. 155. Conclusion The level of HCY is negatively correlated with the level of APTT, FA, VB6, VB12 in serum, positively correlated with FIB. VB6 has dominate effect on HCY metabolism.
出处 《临床内科杂志》 CAS 2009年第4期245-247,共3页 Journal of Clinical Internal Medicine
关键词 同型半胱氨酸 肾病综合征 高凝状态 Homocysteine Nephrotic syndrome Hypercoagulation
  • 相关文献

参考文献10

  • 1Lazzerini PE, Capecchi PL, Selvi E, et al. Hyperhomocysteinemia : a cardiovascular risk factor in autoimmune diseases?. Lupus, 2007, 16: 852-862.
  • 2Hillenbrand R, Hillenbrand A, Liewald F, et al. Hyperhomocysteinemia and recurrent carotid stenosis. BMC Cardiovasc Disord,2008,8:1.
  • 3Ilhan N,Kucuksu M, Kaman D, et al. The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Arch Med Res,2008,39 : 125-130.
  • 4Biselli PM, Sanches de Alvarenga MP, Abbud-Filho M, et al. Effect of folate, vitamin B6 , and vitamin B12 intake and MTHFR C677T polymorphism on homocysteine concentrations of renal transplant recipients. Transplant Proc,2007,39 : 3163-3165.
  • 5Looker HC, Fagot-Campagna A, Gunter EW, et al. Homocysteine and vitamin B( 12 )concentrations and mortality rates in type 2 diabetes. Diabetes Metab Res Rev,2007,23:193-201.
  • 6李冰,薛继强,李春媚.高同型半胱氨酸血症与慢性肾脏疾病相关关系的研究进展[J].临床内科杂志,2008,25(4):287-288. 被引量:8
  • 7Suliman ME, Stenvinkel P, Barany P, et al. Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. Semin Nephrol, 2006, 26 : 14-19.
  • 8Podda GM, Lussana F, Moroni G, et al. Abnormalities of homocysteine and B vitamins in the nephritic syndrome. Thromb Res ,2007,120:647- 652.
  • 9Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease:a randomized controlled trial. JAMA, 2007,298 : 1163-1170.
  • 10Clement L, Boylan M, Miller VG, et al. Serum levels of folate and cobalamin are lower in depressed than in nondepressed hemodialysis subjects. J Ren Nutr,2007 ,17 :343-349.

二级参考文献15

  • 1Biselli PM, Sanches de Alvarenga MP, Abbud-Filho M, et al. Effect of folate, vitamin B6 ,and vitamin B12 intake and MTHFR C677T polymorphism on homocysteine concentrations of renal transplant recipients. Transplant Proc,2007,39:3163-3165.
  • 2Lazzerini PE, Capecchi PL, Selvi E, et al. Hyperhomocysteinemia : a cardiovascular risk factor in autoimmune diseases? Lupus,2007,16:852- 862.
  • 3Hillenbrand R, Hillenbrand A, Liewald F, et al. Hyperhomocysteinemia and recurrent carotid stenosis. BMC Cardiovasc Disord ,2008,8:1.
  • 4Ilhan N, Kueuksu M, Kaman D, et al. The 677 C/T MTHFR polymorphism is associated with essential hypertension,coronary artery disease, and higher homocysteine levels. Arch Med Res,2008,39:125-130.
  • 5Boger CA, Stubanus M, Haak T, et al. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nephrol Dial Transplant ,2007,22 : 154-162.
  • 6Garibotto G, Sofia A, Valli A, et al. Causes of hyperhomocysteinemia in patients with chronic kidney diseases. Semin Nephrol,2006 ,26 :1-7.
  • 7Wotherspoon F, Laight DW, Browne DL,et al. Plasma homocysteine, oxidative stress and endothelial function in patients with Type 1 diabetes mellitus and microalbuminuria. Diabet Med,2006,23:1350-1356.
  • 8Marcus J, Sarnak M J, Menon V. Homocysteine lowering and cardiovascular disease risk : lost in translation. Can J C ardiol, 2007,23 : 707 -710.
  • 9Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homoeysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease:a randomized controlled trial. JAMA ,2007, 298 : 1163-1170.
  • 10Jaar BG, Plantinga LC, Astor BC, et al. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv Chronic Kidney Dis ,2007,14:304-313.

共引文献7

同被引文献18

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部